表紙
市場調查報告書
商品編碼
987863

尿路感染(UTI)治療的全球市場(2020-2027)

Global Urinary Tract Infection Therapeutics Market - 2020-2027

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全世界泌尿道感染(UTI)治療的主要市場推動因素包括糖尿病和腎結石的患病率增加,新診斷技術的引入以及伴隨藥物的推出。按藥物類型而言,氙氣佔有最大份額,並且從適應症來看,對複雜尿路感染的需求佔大多數。按區域劃分,北美國家是最大的市場,而亞太地區也在經歷快速的市場增長。

本報告分析了尿路感染(UTI)治療藥物的全球市場,並根據藥物類型,適應症,分銷渠道和地區預測了市場規模趨勢和詳細趨勢,我們正在調查主要的市場推廣/限制因素。 ,主要公司的資料等。

目錄

第1章全球尿道感染治療藥物市場:分析方法/範圍

第2章全球尿道感染疾病治療市場:市場定義和概述

第3章全球尿道感染治療市場:執行摘要

第4章全球尿道傳染病治療市場:市場動態

  • 影響市場的因素
    • 促進因素
    • 抑製器
    • 市場機會
    • 影響分析

第5章全球尿道感染治療市場:行業分析

  • 波特的五種力量分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST分析
  • 價格分析
  • 監管分析
  • 贖回分析
  • 未滿足的需求
  • 專利趨勢

第6章全球泌尿道感染治療市場:冠狀病毒感染分析(COVID-19)

  • 分析COVID-19對市場的影響
    • "電暈之前"/過去的市場情景
    • "有電暈"/當前市場情景
    • "電暈之後"/未來市場情景
  • COVID-19時尚期間的價格趨勢
  • 供需波動區域
  • 傳染病傳播期間政府對市場的態度
  • 每個製造商的戰略發展狀況
  • 結論

第7章全球尿道感染治療藥物市場:按藥物類型

  • 簡介
  • 市場規模分析和同比增長率(yoy):按藥物類型劃分
  • 市場向心力指數:按藥物類型劃分
    • 青黴素/複合藥物
    • 奎諾酮
    • 頭孢菌素
    • Azole兩性黴素B
    • 硝基夫喃
    • 其他

第8章全球尿道感染治療藥物市場:按適應症

  • 簡介
  • 市場規模分析和同比增長率(YoY):按指標
  • 市場向心力指數:按指示
    • 複雜的尿路感染
    • 單純性尿路感染
    • 其他

第9章:全球尿道傳染病治療市場:通過分銷渠道

  • 簡介
  • 市場規模分析和同比增長率(YoY):按分銷渠道
  • 市場向心力指數:按分銷渠道
    • 醫院藥房
    • 零售藥房
    • 在線藥房

第10章全球尿道感染治療市場:按地區

  • 簡介
  • 市場規模分析和同比增長率(YoY):按地區
  • 市場向心力指數:按地區
  • 北美
    • 簡介
    • 區域市場的獨特趨勢
    • 市場規模分析和同比增長率(yoy):按藥物類型劃分
    • 市場規模分析和同比增長率(YoY):按指標
    • 市場規模分析和同比增長率(YoY):按分銷渠道
    • 市場規模分析和同比增長率(yoy):按國家
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第11章全球尿道感染治療市場:競爭狀況

  • 競爭情景
  • 市場定位/份額分析
  • 併購分析(併購)

第12章全球尿道感染治療市場:公司概況

  • Cipla Ltd.
    • 公司簡介
    • 產品組合/概述
    • 最新趨勢
    • 財務分析:概述
  • AstraZeneca Plc
  • Bayer AG
  • Becton, Dickinson, and Company
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Iterum Therapeutics plc
  • Johnson & Johnson Services Inc.
  • Novartis AG
  • Sinovant Sciences HK Ltd.

第13章全球尿道感染治療市場:重要考慮因素

第14章關於DataM Intelligence

目錄

Market Overview

Urinary Tract Infection (UTI) occurs when bacteria penetrate the urethra and infects the urinary bladder, instigating severe health issues. It is considered a common health problem in females compared to males. Antibiotics are typically the first line of treatment recommended by doctors for the treatment of urinary tract infections. Excessive and uncontrolled passing of urine at night and the painful and increased frequency of urination are the widespread symptoms related to UTI.

The global urinary tract infection therapeutics market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).

Market Dynamics

Certain factors that are leading the market growth include the increasing prevalence of diabetes and kidney stones, the introduction of emerging technologies for the diagnosis of urinary tract infection, and the launch of combination drugs.

Increasing Prevalence of Diabetes and Kidney Stones

The diabetic population has observed an exponential rise across the globe. Changes in lifestyle, sedentary work, unhealthy eating habits, family history, and reduced physical workouts have led to an increase in obesity, which is the major cause of type 2 diabetes in adults. Moreover, according to the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK), kidney stones are common, and their incidence is rising significantly. Nearly 11.0% of men and 6.0% of women in the US have kidney stones at least once in their lifetime. Considering the rising prevalence of kidney stones and Mellitus globally, the demand for urinary tract infection therapeutics is expected to increase during the forecast period.

Introduction of emerging technologies for diagnosis

Continuous development of advanced technologies for the accurate and timely diagnosis of urinary tract infection is expected to increase the number of diagnosed cases of urinary tract infection, which in turn, will enhance the treatment of patients. Emerging technologies, including biosensors and microfluidics, are expected to enhance the diagnosis of disease, which in turn will boost the urinary tract infection treatment market during the forecast period.

COVID-19 Impact Analysis

A considerable decline in the urinary tract infection therapeutics market value was estimated in 2020 due to the outbreak of the COVID-19 pandemic across the globe. During the COVID-19 outbreak, the lockdown was implemented across the majority of the nations globally, which in turn declined the consumption of unhealthy foods, leading to the decline in the number of cases related to infection, including urinary tract infection. Moreover, the hospital visits were considerably declined during the COVID-19 outbreak, owing to which the urinary tract infection diagnosis declined globally, leading to the downfall of the urinary tract infection therapeutics market in 2020.

Segment Analysis

Based on the drug type, the urinary tract infection therapeutics market has been classified into Penicillin and combinations, quinolones, cephalosporin, azoles and amphotericin B, nitrofurans, and others.

Quinolones lead the market throughout the forecast period

Quinolones segment led the overall market with a share in 2019. A majority of physicians recommend quinolones for the treatment of complicated urinary tract infections. Cephalosporin is considered the second-most common drug recommended for the treatment of complicated urinary tract infections. The prevalence of complicated urinary tract infection is set to escalate during the forecast period, mainly owing to the increasing bacterial resistance in urinary tract infection cases and the rise in recurrence rate for urinary tract infection.

Based on the indication, the urinary tract infection therapeutics market has been classified into complicated urinary tract infections, uncomplicated urinary tract infections, and others.

The complicated urinary tract infection segment dominated the global urinary tract infection therapeutics market in 2019

The complicated urinary tract infection segment accounted for the largest share in the global market in 2019. The prevalence of complicated urinary tract infections is expected to propel at a considerable growth during the forecast period, owing to the excessive use of antibiotics and the rise in drug-resistant bacteria. Comparatively, uncomplicated urinary tract infection does not last longer than complicated urinary tract infection; therefore, the treatment procedure for complicated urinary tract infection contributes relatively more to the growth of the urinary tract infection therapeutics market across the globe.

Geographical Analysis

Based on geography, the study analyzes the urinary tract infection therapeutics market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.

North America leads the global market throughout the forecast period

North America dominated the global urinary tract infection therapeutics market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American urinary tract infection therapeutics market in 2019. The major factors leading to the growth of the market in the region include the well-developed healthcare infrastructure and the high awareness amongst the public regarding the treatment of urinary tract infection. Moreover, the presence of some of the key market players, such as Becton, Dickinson and Company, and Johnson & Johnson Services Inc., is further augmenting the growth of the market in the region.

Moreover, Asia Pacific is expected to project the fastest growth rate in the urinary tract infection therapeutics market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific urinary tract infection therapeutics market during the forecast period. The expansion of the market players in the emerging economies of the region, such as India, Vietnam, is expected to propel the demand for urinary tract infection therapeutics in the region.

Competitive Landscape

The urinary tract infection therapeutics market is highly competitive, owing to the large presence of urinary tract infection therapeutics brands. The key urinary tract infection therapeutics players include Cipla Ltd., Becton, Dickinson, and Company, Bayer AG, Boehringer Ingelheim GmbH, AstraZeneca Plc, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd., Iterum Therapeutics plc, Novartis AG, Johnson & Johnson Services Inc. The crucial players are adopting new product launches and expansion strategies for global growth in the urinary tract infection therapeutics market.

Cipla Ltd.

Overview: Boehringer Ingelheim GmbH was established in 1885 and is based in Ingelheim am Rhein, Germany. By serving innovative drugs, the company focuses on therapeutic areas, including respiratory diseases, metabolic diseases, cardiovascular diseases, oncology, virological diseases, and others. The company has over 51000 employee base and deals in Human Pharma, Animal health, and Biopharma. The company offers innovative therapies for improving diabetic conditions globally.

Product Portfolio: The company's portfolio comprises a wide range of kitchen and laundry appliances.

Why Purchase the Report?

  • Visualize the urinary tract infection therapeutics market segmentation composition by drug type, indication, distribution channel, and region, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in the urinary tract infection therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of urinary tract infection therapeutics market - level 3 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global urinary tract infection therapeutics market report would provide access to an approx. 60 market data tables, 57 figures, and 272 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Urinary Tract Infection Therapeutics Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Urinary Tract Infection Therapeutics Market - Market Definition and Overview

3. Global Urinary Tract Infection Therapeutics Market - Executive Summary

  • 3.1. Market Snippet by Drug Type
  • 3.2. Market Snippet by Indication
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Urinary Tract Infection Therapeutics Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Diabetes and Kidney Stones
      • 4.1.1.2. Launch of Combination Drugs
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with urinary tract infection therapeutics
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Urinary Tract Infection Therapeutics Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. Global Urinary Tract Infection Therapeutics Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Urinary Tract Infection Therapeutics Market - By Drug Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
  • 7.3. Market Attractiveness Index, By Drug Type Segment
    • 7.3.1. Penicillin and Combinations*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Quinolones
    • 7.3.3. Cephalosporin
    • 7.3.4. Azoles and Amphotericin B
    • 7.3.5. Nitrofurans
    • 7.3.6. Others

8. Global Urinary Tract Infection Therapeutics Market - By Indication

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Segment
  • 8.3. Market Attractiveness Index, By Indication Segment
    • 8.3.1. Complicated Urinary Tract Infection*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Uncomplicated Urinary Tract Infection
    • 8.3.3. Others

9. Global Urinary Tract Infection Therapeutics Market - By Distribution Channel

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 9.3. Market Attractiveness Index, By Distribution Channel Segment
    • 9.3.1. Hospital Pharmacies*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Retail Pharmacies
    • 9.3.3. Online Pharmacies

10. Global Urinary Tract Infection Therapeutics Market - By Region

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.3. Market Attractiveness Index, By Region
  • 10.4. North America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. U.S.
      • 10.4.6.2. Canada
      • 10.4.6.3. Mexico
  • 10.5. Europe
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. Germany
      • 10.5.6.2. U.K.
      • 10.5.6.3. France
      • 10.5.6.4. Italy
      • 10.5.6.5. Spain
      • 10.5.6.6. Rest of Europe
  • 10.6. South America
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.6.6.1. Brazil
      • 10.6.6.2. Argentina
      • 10.6.6.3. Rest of South America
  • 10.7. Asia Pacific
    • 10.7.1. Introduction
    • 10.7.2. Key Region-Specific Dynamics
    • 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.7.6.1. China
      • 10.7.6.2. India
      • 10.7.6.3. Japan
      • 10.7.6.4. Australia
      • 10.7.6.5. Rest of Asia Pacific
  • 10.8. Middle East and Africa
    • 10.8.1. Introduction
    • 10.8.2. Key Region-Specific Dynamics
    • 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Global Urinary Tract Infection Therapeutics Market - Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Global Urinary Tract Infection Therapeutics Market- Company Profiles

  • 12.1. Cipla Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. AstraZeneca Plc
  • 12.3. Bayer AG
  • 12.4. Becton, Dickinson, and Company
  • 12.5. Boehringer Ingelheim GmbH
  • 12.6. F. Hoffmann-La Roche Ltd.
  • 12.7. GlaxoSmithKline PLC
  • 12.8. Iterum Therapeutics plc
  • 12.9. Johnson & Johnson Services Inc.
  • 12.10. Novartis AG
  • 12.11. Sinovant Sciences HK Ltd.

LIST NOT EXHAUSTIVE

13. Global Urinary Tract Infection Therapeutics Market - Premium Insights

14. Global Urinary Tract Infection Therapeutics Market - DataM Intelligence

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us